We are live on
!
Find out more
DFO
Duquesne Family Office Portfolio holdings
AUM
$3.38B
1-Year Est. Return
61.92%
This Fund
S&P 500
This Quarter
Est. Return
+2.36%
1 Year Est. Return
+61.92%
3 Year Est. Return
+280.57%
5 Year Est. Return
+393.65%
10 Year Est. Return
+4,147.23%
AUM
$815M
AUM Growth
-$586M
(-42%)
Cap. Flow
-$570M
Cap. Flow
% of AUM
-69.95%
Top 10 Holdings %
Top 10 Hldgs %
56.84%
Holding
69
New
24
Increased
2
Reduced
5
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$25.7M |
| 2 |
Gilead Sciences
GILD
|
+$21.3M |
| 3 |
Amgen
AMGN
|
+$20.7M |
| 4 |
Merck
MRK
|
+$19.4M |
| 5 |
Costco
COST
|
+$19.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$129M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$65.1M |
| 3 |
Meta Platforms (Facebook)
META
|
+$63.8M |
| 4 |
VanEck Gold Miners ETF
GDX
|
+$60M |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
+$38.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.25% |
| 2 | Consumer Discretionary | 16.43% |
| 3 | Communication Services | 12.04% |
| 4 | Materials | 7.93% |
| 5 | Consumer Staples | 4.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alphabet (Google) Class C
GOOG
$4.1T
| $98.2M | 12.04% |
3,345,360
-4,446,374
| -57% | -$129M |
|
2
Illumina
ILMN
$29.1B
| $67.2M | 8.25% |
421,583
| – | – |
|
3
Alcoa
AA
$11.3B
| $64.7M | 7.93% |
1,672,077
-718,268
| -30% | -$28.2M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $53.1M | 6.52% |
560,600
+284,600
| +103% | +$25.7M |
|
|
WBA
5
DELISTED
Walgreens Boots Alliance
WBA
| $38.4M | 4.71% |
648,000
-592,000
| -48% | -$38.8M |
|
6
Biogen
BIIB
$30.9B
| $34.3M | 4.21% |
103,800
| – | – |
|
|
7
VanEck Gold Miners ETF
GDX
$22.5B
| $33M | 4.05% |
1,546,600
-2,348,400
| -60% | -$60M |
|
|
MDR
8
DELISTED
McDermott International
MDR
| $26.1M | 3.2% |
1,518,333
+418,333
| +38% | +$9.02M |
|
9
Cameco
CCJ
$36.9B
| $25.2M | 3.09% |
1,428,200
| – | – |
|
|
10
Gilead Sciences
GILD
$167B
| $23.2M | 2.84% |
+217,500
| New | +$21.3M |
|
|
11
Amgen
AMGN
$211B
| $22.3M | 2.74% |
+158,900
| New | +$20.7M |
|
12
Home Depot
HD
$341B
| $20.4M | 2.5% |
+222,400
| New | +$19.1M |
|
|
13
Costco
COST
$432B
| $19.8M | 2.43% |
+158,100
| New | +$19.1M |
|
14
Kohl's
KSS
$2.13B
| $19.8M | 2.42% |
+323,900
| New | +$18.3M |
|
15
Lowe's Companies
LOW
$122B
| $19.6M | 2.41% |
+370,900
| New | +$18.7M |
|
16
Target
TGT
$66.7B
| $19.6M | 2.4% |
+312,300
| New | +$18.9M |
|
|
17
Merck
MRK
$324B
| $19.5M | 2.4% |
+345,421
| New | +$19.4M |
|
18
Workday
WDAY
$41.5B
| $18.4M | 2.25% |
222,679
| – | – |
|
|
MLNX
19
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $17.5M | 2.14% |
+389,300
| New | +$15.8M |
|
20
Vertex Pharmaceuticals
VRTX
$124B
| $16.5M | 2.02% |
+146,600
| New | +$14M |
|
21
American Eagle Outfitters
AEO
$2.91B
| $14.8M | 1.81% |
+1,017,000
| New | +$12.5M |
|
22
Williams-Sonoma
WSM
$27.4B
| $14.5M | 1.78% |
+435,000
| New | +$15.1M |
|
23
Macy's
M
$6.44B
| $14.3M | 1.76% |
+246,400
| New | +$14.6M |
|
|
SCHW
24
Charles Schwab
SCHW
$185B
| $14.3M | 1.75% |
+485,700
| New | +$13.7M |
|
25
HDFC Bank
HDB
$123B
| $14.3M | 1.75% |
+1,224,000
| New | +$14.8M |
|
Similar funds
VFCM
OAM
EFM
BG
DIA
5NCM
TAM
BCM
Duquesne Family Office's Q3 2014 Portfolio in Review
As of Q3 2014, Duquesne Family Office held 69 positions worth $815M, down 42% from $1.4B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Duquesne Family Office withdrew a net $570M in Q3 2014, closing 33 positions and reducing 5 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $65.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 23% a quarter earlier, followed by Consumer Discretionary and Communication Services.
Against the trend, Duquesne Family Office opened a new position in Gilead Sciences worth $23.2M.
- Duquesne Family Office's largest Q3 2014 buy was Gilead Sciences: 217,500 shares worth $23.2M.
- Duquesne Family Office added most to Celgene Corp in Q3 2014, an estimated $25.7M increase.
- Duquesne Family Office's biggest Q3 2014 reduction was Alphabet (Google) Class C, cutting an estimated $129M.
- Duquesne Family Office fully exited Teva Pharmaceuticals in Q3 2014, selling an estimated $65.1M.
- Duquesne Family Office's ten largest holdings make up 57% of its $815M portfolio in Q3 2014.
- Duquesne Family Office opened 24 new positions and closed 33 in Q3 2014.
- Duquesne Family Office's portfolio value fell 42% quarter-over-quarter to $815M.
Based on Duquesne Family Office's 13F filing for Q3 2014, filed 14 Nov 2014.